Integrating hemorheological data with established biomarkers—such as the neutrophil-to-lymphocyte ratio, CRP levels, or circulating tumor DNA—will further facilitate the distinction between immunotherapy-related alterations and systemic responses, creating a more reliable predictive framework [1,2,3]. This evidence concerns the gene CRP and neoplasm.